The FDA New Drug Application (NDA) and EMA Marketing Authorization Application (MAA) submissions for etavopivat are based on data from the Phase 3 HIBISCUS trial showing efficacy and safety results in adolescents and adults living with sickle cell disease1 Sickle cell disease is a...